Form 4: Pacira BioSciences SVP Finance Executes Tax Withholding

Lauren Riker, Senior Vice President of Finance at Pacira BioSciences, Inc., reported the withholding of 3,187 shares to cover tax obligations.

Summary

• Lauren Riker, Senior Vice President of Finance, disposed of 3,187 shares of Pacira BioSciences common stock.
• The transaction occurred on June 3, 2026, at a price of $22.32 per share.
• The disposal was executed via a 'F' code transaction, representing shares withheld by the issuer to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Following this transaction, the reporting person maintains a direct beneficial ownership of 68,399.242 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a mandatory administrative filing for tax purposes and does not reflect a change in the executive's outlook on the company.

Positives

• The transaction is a routine administrative action related to tax obligations upon the vesting of equity awards, rather than a discretionary market sale.

Negatives

• Reduction in the total number of shares held by a member of the senior management team.

Risks

• None identified; this is a standard regulatory disclosure for tax withholding.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that routine tax withholding filings are standard practice for executives in the biotechnology sector and do not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for equity compensation management in the U.S. pharmaceutical industry.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a non-discretionary tax settlement.

Next Steps

• None identified.

Key Dates

Keywords

Pacira BioSciences, PCRX, Insider Trading, Form 4, Tax Withholding, Equity Vesting